Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
Despina EleftheriouYolanda Collaco MoraesCara PurvisMolly PursellMarta Merida MorillasRobin KahnMaria MossbergFilip KuceraRobert TullohJoseph F StandingVeronica SwallowRachael McCormackJethro HerbergMichael LevinMandy WanNigel KleinRoisin ConnonAnn Sarah WalkerPaul BroganPublished in: Trials (2023)
ISRCTN71987471- March 31, 2020; Eudract 2019-004433-17.
Keyphrases
- open label
- study protocol
- phase iii
- phase ii
- clinical trial
- coronary artery
- randomized controlled trial
- low dose
- placebo controlled
- cardiovascular events
- double blind
- phase ii study
- antiplatelet therapy
- pulmonary artery
- high dose
- coronary artery disease
- cardiovascular disease
- type diabetes
- pulmonary hypertension
- anti inflammatory drugs
- acute coronary syndrome
- atrial fibrillation
- percutaneous coronary intervention
- pulmonary arterial hypertension